Jiang 10 et al
#Pharma #ProductManagement #DrugDevelopment #Obesity #GLP1 #Orforglipron #Foundayo #HealthcareInnovation #PharmaceuticalIndustry #LifeSciences #MedicalAffairs #ClinicalResearch #MarketAccess #PatientCentricity #PharmaMarketing To view or add a comment, sign in Eli Lilly announced positive results from two additional Phase 3 trials of retatrutide, bringing the investigational obesity drug closer to FDA approval
Where the anti-obesity benefit is included in the employer plan, Harvard Pilgrim requires prior authorization with BMI 30 or higher (or 27 with a weight-related comorbidity such as hypertension, T2D, dyslipidemia, or sleep apnea), documented lifestyle program participation, and demonstrated weight-loss progress for renewal
The look is usually a mix of collagen loss, water loss from the barrier, and subtle laxity that shows in certain lighting
Supporting Tissue Biology Still Matters Most Lipedema care requires DIRECT support for: Microcirculation Lymphatic flow Inflammation balance Oxidative stress Nerve sensitivity Connective tissue integrity That is the area where targeted supplements like Lipera are essential whether or not someone uses GLP-1s
